Search results
Results from the WOW.Com Content Network
Abemaciclib, sold under the brand name Verzenio among others, is a medication for the treatment of advanced or metastatic breast cancers. It was developed by Eli Lilly and it acts as a CDK inhibitor selective for CDK4 and CDK6. [4] It was designated as a breakthrough therapy for breast cancer by the US Food and Drug Administration (FDA) in ...
Medroxyprogesterone acetate (Amen, Curretab, Cycrin, Provera) – 2.5 mg, 5 mg, 10 mg; Megestrol acetate (Megace) – 20 mg, 40 mg – approved specifically for the treatment of breast and endometrial cancer [46] and for the treatment of anorexia, cachexia, and weight loss in patients with AIDS Tooltip acquired immunodeficiency syndrome [47]
Aromatase inhibitors (AIs) are a class of drugs used in the treatment of breast cancer in postmenopausal women and in men, [1] [2] and gynecomastia in men. They may also be used off-label to reduce estrogen conversion when supplementing testosterone exogenously. They may also be used for chemoprevention in women at high risk for breast cancer.
Fulvestrant, sold under the brand name Faslodex among others, is an antiestrogenic medication used to treat hormone receptor (HR)-positive metastatic breast cancer in postmenopausal women with disease progression as well as HR-positive, HER2-negative advanced breast cancer in combination with abemaciclib or palbociclib in women with disease progression after endocrine therapy. [2]
Now, approved for weight loss under the name Zepbound, the drug is available in six doses—2.5, 5, 7.5, 10, 12.5, and 15 milligrams, according to Eli Lilly, which makes the injectable medication ...
Selinexor sold under the brand name Xpovio among others, is a selective inhibitor of nuclear export used as an anti-cancer medication.It works by blocking the action of exportin 1 [6] and thus blocking the transport of several proteins involved in cancer-cell growth from the cell nucleus to the cytoplasm, which ultimately arrests the cell cycle and leads to apoptosis. [8]
The pancreatic cancer trials found that gemcitabine increased one-year survival rate significantly, and it was approved in the UK in 1995 [10] and approved by the FDA in 1996 for pancreatic cancers. [4] In 1998, gemcitabine received FDA approval for treating non-small cell lung cancer and in 2004, it was approved for metastatic breast cancer. [4]
Women post-menopause with ‘strong family history’ of breast cancer encouraged speak to GP about drug, expert says